397 related articles for article (PubMed ID: 24634471)
21. Overactivated neddylation pathway as a therapeutic target in lung cancer.
Li L; Wang M; Yu G; Chen P; Li H; Wei D; Zhu J; Xie L; Jia H; Shi J; Li C; Yao W; Wang Y; Gao Q; Jeong LS; Lee HW; Yu J; Hu F; Mei J; Wang P; Chu Y; Qi H; Yang M; Dong Z; Sun Y; Hoffman RM; Jia L
J Natl Cancer Inst; 2014 Jun; 106(6):dju083. PubMed ID: 24853380
[TBL] [Abstract][Full Text] [Related]
22. Mutations in UBA3 confer resistance to the NEDD8-activating enzyme inhibitor MLN4924 in human leukemic cells.
Xu GW; Toth JI; da Silva SR; Paiva SL; Lukkarila JL; Hurren R; Maclean N; Sukhai MA; Bhattacharjee RN; Goard CA; Medeiros B; Gunning PT; Dhe-Paganon S; Petroski MD; Schimmer AD
PLoS One; 2014; 9(4):e93530. PubMed ID: 24691136
[TBL] [Abstract][Full Text] [Related]
23. Quantitative proteomic analysis of cellular protein modulation upon inhibition of the NEDD8-activating enzyme by MLN4924.
Liao H; Liu XJ; Blank JL; Bouck DC; Bernard H; Garcia K; Lightcap ES
Mol Cell Proteomics; 2011 Nov; 10(11):M111.009183. PubMed ID: 21873567
[TBL] [Abstract][Full Text] [Related]
24. NEDD8-activating enzyme inhibitor, MLN4924 (Pevonedistat) induces NOXA-dependent apoptosis through up-regulation of ATF-4.
Liu X; Jiang Y; Wu J; Zhang W; Liang Y; Jia L; Yu J; Jeong LS; Li L
Biochem Biophys Res Commun; 2017 Jun; 488(1):1-5. PubMed ID: 28450112
[TBL] [Abstract][Full Text] [Related]
25. STAT3 and NF-κB cooperatively control in vitro spontaneous apoptosis and poor chemo-responsiveness in patients with chronic lymphocytic leukemia.
Liu FT; Jia L; Wang P; Wang H; Farren TW; Agrawal SG
Oncotarget; 2016 May; 7(22):32031-45. PubMed ID: 27074565
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia.
Swords RT; Kelly KR; Smith PG; Garnsey JJ; Mahalingam D; Medina E; Oberheu K; Padmanabhan S; O'Dwyer M; Nawrocki ST; Giles FJ; Carew JS
Blood; 2010 May; 115(18):3796-800. PubMed ID: 20203261
[TBL] [Abstract][Full Text] [Related]
27. Suppression of tumor angiogenesis by targeting the protein neddylation pathway.
Yao WT; Wu JF; Yu GY; Wang R; Wang K; Li LH; Chen P; Jiang YN; Cheng H; Lee HW; Yu J; Qi H; Yu XJ; Wang P; Chu YW; Yang M; Hua ZC; Ying HQ; Hoffman RM; Jeong LS; Jia LJ
Cell Death Dis; 2014 Feb; 5(2):e1059. PubMed ID: 24525735
[TBL] [Abstract][Full Text] [Related]
28. Ubiquitin E3 ligase CRL4(CDT2/DCAF2) as a potential chemotherapeutic target for ovarian surface epithelial cancer.
Pan WW; Zhou JJ; Yu C; Xu Y; Guo LJ; Zhang HY; Zhou D; Song FZ; Fan HY
J Biol Chem; 2013 Oct; 288(41):29680-91. PubMed ID: 23995842
[TBL] [Abstract][Full Text] [Related]
29. Targeting the protein ubiquitination machinery in melanoma by the NEDD8-activating enzyme inhibitor pevonedistat (MLN4924).
Wong KM; Micel LN; Selby HM; Tan AC; Pitts TM; Bagby SM; Spreafico A; Klauck PJ; Blakemore SJ; Smith PF; McDonald A; Berger A; Tentler JJ; Eckhardt SG
Invest New Drugs; 2017 Feb; 35(1):11-25. PubMed ID: 27783255
[TBL] [Abstract][Full Text] [Related]
30. DHMEQ, a new NF-kappaB inhibitor, induces apoptosis and enhances fludarabine effects on chronic lymphocytic leukemia cells.
Horie R; Watanabe M; Okamura T; Taira M; Shoda M; Motoji T; Utsunomiya A; Watanabe T; Higashihara M; Umezawa K
Leukemia; 2006 May; 20(5):800-6. PubMed ID: 16525497
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of BCR signaling using the Syk inhibitor TAK-659 prevents stroma-mediated signaling in chronic lymphocytic leukemia cells.
Purroy N; Carabia J; Abrisqueta P; Egia L; Aguiló M; Carpio C; Palacio C; Crespo M; Bosch F
Oncotarget; 2017 Jan; 8(1):742-756. PubMed ID: 27888629
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of neddylation represses lipopolysaccharide-induced proinflammatory cytokine production in macrophage cells.
Chang FM; Reyna SM; Granados JC; Wei SJ; Innis-Whitehouse W; Maffi SK; Rodriguez E; Slaga TJ; Short JD
J Biol Chem; 2012 Oct; 287(42):35756-35767. PubMed ID: 22927439
[TBL] [Abstract][Full Text] [Related]
33. BIRC3 Expression Predicts CLL Progression and Defines Treatment Sensitivity via Enhanced NF-κB Nuclear Translocation.
Asslaber D; Wacht N; Leisch M; Qi Y; Maeding N; Hufnagl C; Jansko B; Zaborsky N; Villunger A; Hartmann TN; Greil R; Egle A
Clin Cancer Res; 2019 Mar; 25(6):1901-1912. PubMed ID: 30487125
[TBL] [Abstract][Full Text] [Related]
34. Immunomodulatory effects of pevonedistat, a NEDD8-activating enzyme inhibitor, in chronic lymphocytic leukemia-derived T cells.
Best S; Lam V; Liu T; Bruss N; Kittai A; Danilova OV; Murray S; Berger A; Pennock ND; Lind EF; Danilov AV
Leukemia; 2021 Jan; 35(1):156-168. PubMed ID: 32203139
[TBL] [Abstract][Full Text] [Related]
35. Bone marrow stroma-induced resistance of chronic lymphocytic leukemia cells to arsenic trioxide involves Mcl-1 upregulation and is overcome by inhibiting the PI3Kδ or PKCβ signaling pathways.
Amigo-Jiménez I; Bailón E; Aguilera-Montilla N; Terol MJ; García-Marco JA; García-Pardo A
Oncotarget; 2015 Dec; 6(42):44832-48. PubMed ID: 26540567
[TBL] [Abstract][Full Text] [Related]
36. The Effect of Neddylation Inhibition on Inflammation-Induced MMP9 Gene Expression in Esophageal Squamous Cell Carcinoma.
Hryniewicz-Jankowska A; Wierzbicki J; Tabola R; Stach K; Sossey-Alaoui K; Augoff K
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33572115
[TBL] [Abstract][Full Text] [Related]
37. Suppression of glioblastoma by targeting the overactivated protein neddylation pathway.
Hua W; Li C; Yang Z; Li L; Jiang Y; Yu G; Zhu W; Liu Z; Duan S; Chu Y; Yang M; Zhang Y; Mao Y; Jia L
Neuro Oncol; 2015 Oct; 17(10):1333-43. PubMed ID: 25904638
[TBL] [Abstract][Full Text] [Related]
38. The BET inhibitor GS-5829 targets chronic lymphocytic leukemia cells and their supportive microenvironment.
Kim E; Ten Hacken E; Sivina M; Clarke A; Thompson PA; Jain N; Ferrajoli A; Estrov Z; Keating MJ; Wierda WG; Bhalla KN; Burger JA
Leukemia; 2020 Jun; 34(6):1588-1598. PubMed ID: 31862959
[TBL] [Abstract][Full Text] [Related]
39. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.
Herman SE; Gordon AL; Hertlein E; Ramanunni A; Zhang X; Jaglowski S; Flynn J; Jones J; Blum KA; Buggy JJ; Hamdy A; Johnson AJ; Byrd JC
Blood; 2011 Jun; 117(23):6287-96. PubMed ID: 21422473
[TBL] [Abstract][Full Text] [Related]
40. Targeting metabolism and survival in chronic lymphocytic leukemia and Richter syndrome cells by a novel NF-κB inhibitor.
Vaisitti T; Gaudino F; Ouk S; Moscvin M; Vitale N; Serra S; Arruga F; Zakrzewski JL; Liou HC; Allan JN; Furman RR; Deaglio S
Haematologica; 2017 Nov; 102(11):1878-1889. PubMed ID: 28860341
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
